Most growth factors and hormones are synthesized as prepro-proteins which are processed to the biologically active mature protein. The pre-and prodomains are cleaved from the precursor protein in the secretory pathway or, in some cases, extracellularly. The canonical functions of these prodomains are to assist in folding and stabilization of the mature domain, to direct intra and extracellular localization, to facilitate storage, and to regulate bioavailability of their mature counterpart. Recently, exciting evidence has revealed that prodomains of certain growth factors, after cleaved from the precursor pro-protein, can act as independent active signaling molecules. In this review, we discuss the various classical functions of prodomains, and the biological consequences of these pro-peptides acting as ligands. We will focus our attention on the brain-derived neurotrophic factor prodomain (pBDNF), which has been recently described as a novel secreted ligand influencing neuronal morphology and physiology. Keywords: active prodomains, biosynthetic pathway, pBDNF, precursor cleavage peptides, proBDNF, Val66Met polymorphism. Most growth factors and hormones are synthetized as prepro-proteins. These prefixes are used to describe the intermediate processed forms of a protein before it is active and at the appropriate location. The prefix 'pre' indicates the presence of an N-terminal sequence that targets the precursor pro-protein to the secretory pathway or an intracellular compartment. For this reason, this sequence is referred to as 'signal peptide' or 'signal sequence'. Signal peptides, which are typically from 5 to 50 residues, are cleaved by signal peptidases and quickly degraded. Later, it was discovered that many proteins require additional proteolytic processing to become functional. This additional step involves cleavage of a subsequent N-terminal peptide, which is indicated by the prefix 'pro' accounting for prodomain (or pro-peptide; example in Fig. 1a) . The processing of pro-proteins to remove their prodomains requires enzymes including proprotein convertases (or proconvertases), which are present in the Golgi apparatus or in secretory vesicles, or extracellular enzymes such as matrix metalloproteinases among others. For example, the pro-protein of the neurotrophin brainderived neurotrophic factor (proBDNF), can be cleaved by furin and other proconvertases in the trans-Golgi network or Received December 29, 2016; revised manuscript received February 8, 2017; accepted February 13, 2017. Address correspondence and reprint requests to Agustin Anastasia, Instituto de Investigaci on M edica Mercedes y Martin Ferreyra, (INIMEC-CONICET-Universidad Nacional de C ordoba), Friuli 2434, C ordoba, C ordoba 5016, Argentina. E-mail: aanastasia@immf.uncor.edu.
Most growth factors and hormones are synthetized as prepro-proteins. These prefixes are used to describe the intermediate processed forms of a protein before it is active and at the appropriate location. The prefix 'pre' indicates the presence of an N-terminal sequence that targets the precursor pro-protein to the secretory pathway or an intracellular compartment. For this reason, this sequence is referred to as 'signal peptide' or 'signal sequence'. Signal peptides, which are typically from 5 to 50 residues, are cleaved by signal peptidases and quickly degraded. Later, it was discovered that many proteins require additional proteolytic processing to become functional. This additional step involves cleavage of a subsequent N-terminal peptide, which is indicated by the prefix 'pro' accounting for prodomain (or pro-peptide; example in Fig. 1a ). The processing of pro-proteins to remove their prodomains requires enzymes including proprotein convertases (or proconvertases), which are present in the Golgi apparatus or in secretory vesicles, or extracellular enzymes such as matrix metalloproteinases among others. For example, the pro-protein of the neurotrophin brainderived neurotrophic factor (proBDNF), can be cleaved by furin and other proconvertases in the trans-Golgi network or secretory vesicles (Mowla et al. 2001; Teng et al. 2010) . In addition, proBDNF can be processed extracellularly by plasmin generated by tissue plasminogen activator or by selective matrix metalloproteinases (MMPs) including MMP3, MMP7 (Lee et al. 2001) , and MMP9 (Mizoguchi et al. 2011) to release the prodomain (pBDNF) and mature BDNF (mBDNF) (reviewed in Hempstead 2015; Mizui et al. 2016) (Fig. 1a) . In many cases, more than one biologically active cleavage product is generated from one pro-protein precursor. Prodomains were thought to merely assist mature domains during biosynthesis (see below in 'established prodomains functions'). However, recent evidence demonstrates that prodomains can be independent active peptides which often display different biological activities than other cleavage products from the precursors. Discussing the recent literature, this review highlights new biological functions of growth factor and hormone prodomains beyond the classical roles in the biosynthetic pathway.
Established prodomains functions
In general, prodomains can (1) promote protein stabilization and proper folding, (2) direct intracellular trafficking, (3) participate in protein storage, (4) regulate extracellular distribution, or (5) shield mature domains from receptors to limit bioavailability. These biological roles are discussed below.
(1) Many proteins fold poorly or are misfolded in the absence of their prodomains. For that reason, they are often referred to as 'intramolecular chaperones' (Inouye 1991) . In vitro folding studies suggested that prodomains stabilize folding intermediate states. Prodomains presumably work as scaffold peptides which guide the intermediate, low energy states, to the native active conformation (Rattenholl et al. 2001b) . As an example, the nerve growth factor (NGF) prodomain was found to be essential for the proper folding of active mature NGF (mNGF). Mutagenesis of a critical region comprising amino acids 67-94 (27 residues) within the NGF Fig. 1 Brain-derived neurotrophic factor (BDNF) precursor (proBDNF) structure and BDNF prodomain (pBDNF) effects on neurons. (a) Prepro-BDNF domains. The prefix 'pre' indicates the presence of signal peptide (SP). The prefix 'pro' points the prodomain (also named or propeptide) which is also cleaved enzymatically. BDNF prodomain: pBDNF. Mature BDNF: mBDNF. There is a human single nucleotide polymorphism inducing a substitution of a valine in position 66 for a methionine within the prodomain sequence (Val66Met). N-= aminoterminus; C-= carboxyl-terminus. (b-f) Three independent laboratories have studied pBDNF activity. (b-c) The first study found that only the Met variant of pBDNF acutely alters neuronal morphology inducing changes in neuron growth cones (correlated with a decrease in Rac activity), while the Val-pBDNF was inert (Anastasia et al. 2013) . The Val-pBDNF is drawn with tendency to b-structure, while the Met version with some helical structure. (d-e) The second study showed that the Val-pBDNF facilitate hippocampal long-term depression by inducing an increase in surface expression of the GluN2B subunit of the NMDA receptor and the consequent a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) internalization. The Met variant prevented this effect (Mizui et al. 2015) . (f) The third report found that the Val-pBDNF reduces dendritic spine density in hippocampal neurons through a pathway involving mitochondrial release of cytochrome c (CytoC) and caspase 3 (Casp3) activation (Guo et al. 2016) .
prodomain sequence showed impaired expression of biologically active mNGF (Suter et al. 1991) . Moreover, the NGF prodomain has been shown to enhance mNGF folding yields and kinetics, and to assist in its disulfide bond formation (Rattenholl et al. 2001b) . The same study suggested that the NGF prodomain function would be to facilitate the formation of the characteristic cysteine knot of neurotrophins (Wiesmann et al. 1999; He and Garcia 2004; Gong et al. 2008; Feng et al. 2010) and/or would passively confer solubility to the folding intermediates shielding hydrophobic patches to enhance folding yields. The NGF prodomain also augments the yield and rate of refolding of mNGF from Escherichia coli inclusion bodies (Rattenholl et al. 2001a) . In addition, the mNGF domain can in turn stabilize the structure of its prodomain (Kliemannel et al. 2004) . Prodomain-dependent folding of the mature sequences can occur in 'trans'. For instance, the neurotrophin 3 (NT-3) prodomain can promote structure and folding of mNGF (Hauburger et al. 2007) . The relevance of this prodomain interchangeability remains to be clarified in vivo and would only be biologically relevant when these two proteins are co-expressed in the same local. The prodomain-dependent folding in 'trans' suggests that the prodomains' chaperone activity is conserved in the neurotrophin family.
(2) Prodomains might interact with chaperones to direct their intracellular trafficking to their final subcellular destination. A very well documented example of this process is the interaction of the BDNF prodomain with the Vps10p domain protein sortilin in the trafficking of its precursor proBDNF. Chen and collaborators have found that sortilin interacts specifically with residues 44-103 of the prodomain (Chen et al. 2005) . Utilizing different mutants for the transmembrane and intracellular domains of sortilin they showed that proBDNF was mislocalized as it was more diffusely distributed in the cell body with minimal staining in the processes. Moreover, mutant-sortilin transfected cells exhibited decreased colocalization of proBDNF with the secretory granule maker SecII (Chen et al. 2005) . This sortilin-proBDNF interaction was shown to regulate activitydependent secretion of mBDNF (Chen et al. 2005) . Other proteins such as the somatostatin and myeloperoxidase require their prodomains for targeting of the mature protein to the regulated secretory pathway (Sevarino et al. 1989; Andersson et al. 1998) .
A common single nucleotide polymorphism (SNP) in the human BDNF gene leads to a nucleotide change from a guanine to an adenine at position 196 (G196A) that results in a valine (Val) to methionine (Met) substitution at codon 66 (Val66Met) in the middle of the pBDNF sequence (Fig. 1a) . This SNP is observed in more than 25% of the human population (Database of Single-nucleotide Polymorphisms (dbSNP) 2012), and is associated with alterations in fear memory regulation and enhanced risk for depression and anxiety disorders as well as with some neurodegenerative disorders in humans (Egan et al. 2003; Martinowich et al. 2007; Frielingsdorf et al. 2010; Soliman et al. 2010; Verhagen et al. 2010; Dincheva et al. 2012; Hajek et al. 2012) . Interestingly, the Met proBDNF variant exhibits decreased binding to sortilin, altered intracellular trafficking, and a reduction in the activity-dependent secretion of mBDNF (Egan et al. 2003; Chen et al. 2004 Chen et al. , 2005 . Moreover, knock-in mice that express the Val66Met SNP recapitulates specific phenotypic properties of the human polymorphism (Chen et al. 2006) . Thus, their proposed mechanism by which Met allele mediates central nervous system effects is indirect, by a reduction in activity-dependent release of mBDNF leading to altered synaptic plasticity. A complementary mechanism for the deleterious function of the Met allele has been reported (Anastasia et al. 2013) and will be discussed later in this review.
(3) Prodomains are thought to optimize storage space in granules and vesicles by promoting multimerization and aggregation of the pro-proteins and/or mature peptides. Moreover, this aggregation might prevent proteolytic enzymes access and augment proteins half-life. For instance, the prodomain of von Willebrand factor (VWF), a glycoprotein that participates in wound healing and coagulation, is needed for the proper processing and storage of the mature protein. The VWF prodomain is required for multimerization of the VWF and to target this factor to storage granules, while the mature VWF expressed alone is not stored. However, the expression of the mature and prodomain together either in cis (in one polypeptide) or in trans (in two separate polypeptides) results in the granular storage of both moieties (Haberichter 2015) .
(4-5) Transforming growth factor b (TGFb) family members are also synthetized as precursors (proTGFbs), with an N-terminal prodomain and a mature domain, which are processed intracellularly by furin and proconvertases. Interestingly, the prodomains continue to interact with their mature domains after cleavage of the precursor, and even after secretion. This interaction is non-covalent and maintains the molecules in a conformation capable of dimerization. For many TGFb family members, the mature-prodomain association persists in the extracellular matrix where the prodomain interacts with some of its components such as fibrillin and perlecan. The interaction of prodomains with the matrix components assists the mature TGFb domains to localize near their target cells. Another consequence of this prodomain-mature domain interaction is to confer latency of some TGFb family members. The prodomains of TGFb1, TGFb2, TGFb3, myostatin, growth differentiation factor 11 (GDF11), and bone morphogenetic protein 10 (BMP10) bind with enough affinity to their mature domains that are capable of suppressing their biological activity, adding a step at which the ligand's availability can be regulated. On the other hand, the prodomains of other BMPs do not bind strongly enough to prevent the mature domain from interacting with their receptors and trigger signaling (Gregory et al. 2005; Sengle et al. 2011; Bidart et al. 2012) . Recently it has been proposed that there is an 'open-armed' structure that does not preclude the activity of BMP9 interacting with its prodomain, while the 'cross-armed' feature observed in TGFb1-prodomain complex confers the latent conformation (Mi et al. 2015) . The authors also suggest that interactors in the extracellular matrix stabilize a cross-armed conformation and regulate the transition between cross-armed (latent) and open-armed (non-latent) conformations of some TGFb family members (Mi et al. 2015) . Another mechanism has been found for the release of mature domains of TGFbs proteins from the inhibitory interaction with prodomains: activation of TGFb1 requires the binding of integrin to an arginine/glycine/aspartic acid sequence within the prodomain sequence and exertion of force on this domain to disengage both peptides and release the active mature protein (Shi et al. 2011) . Besides these proposed mechanisms, activation of other TGFb family members depend on the cell type and context, but always requires targeting of their prodomains. In all, prodomains control many aspects of TGFb family biology as they regulate the activation of these multifunctional cytokines. A recent structural study demonstrates that also platelet-derived growth factor stably binds to its prodomain. The regions of interaction between the mature and prodomain are those that mediate the interface with its receptor (Shim et al. 2010) . Thus, this report suggests that the platelet-derived growth factor prodomain-mature domain complex may prevent receptor activation, and implies that the inhibitory-effects of prodomains can be conserved (to some degree).
Prodomains as part of active pro-protein precursors
Besides the classic prodomain functions described above, prodomains can also be part of biologically active precursors. Some precursors have biological functions and act via receptors that are different from those of their cleaved mature domains. These active pro-proteins include the precursor of cerebellin, the family of chromogranins/secretogranins, proapolipoprotein (apo) A1, procorticotrophin-releasing hormone, progastrin, prograstrin-releasing peptide, parathyroid hormone-related protein, proenkephalin, and the proneurotrophins (reviewed in Dicou 2008 ). The proneurotrophins, from which we have already described some aspects of proNGF and proBDNF above, is a family of precursors that were discovered to signal independently and with distinct functions from their mature counterparts (Lee et al. 2001) . While mature neurotrophins bind a tropomyosin-related kinase (Trk) receptor to promote neuronal survival, differentiation, neurogenesis and synaptic plasticity, the proneurotrophins proNGF and proBDNF, interact with a receptor complex of p75 neurotrophin receptor (p75NTR) and sortilin (a Vps10p-domain sorting receptor) to induce apoptosis and morphological changes in cell lines, smooth muscle cells, Schwann cells, and primary neurons in culture (Lee et al. 2001; Ibanez 2002; Nykjaer et al. 2004; Teng et al. 2005; Jansen et al. 2007; Willnow et al. 2008; Song et al. 2010; Je et al. 2012) . Likewise, the unprocessed neurotrophin 3 (proNT3) triggers apoptosis in inner ear neurons and sympathetic neurons which co-express p75NTR and sortilin (Yano et al. 2009; Tauris et al. 2011) . Application of proBDNF to p75NTR-expressing hippocampal or entorhinal slices enhanced long-term depression (LTD) (Woo et al. 2005) and suppressed persistent firing (Gibon et al. 2015) , respectively. These results suggest that proBDNF can also act as an endogenous ligand to directly regulate LTD and to control neuron excitability. Recently, Yang and collaborators showed that a cleavage-resistant proBDNF knock-in mouse displays decreased hippocampal dendritic complexity, reduced spine density and enhanced LTD in the CA1 region of the hippocampus (Yang et al. 2014) . These results confirm previous observations by Woo and collaborators (Woo et al. 2005) , and suggest that proBDNF acts in vivo regulating hippocampal structure and plasticity. ProBDNF functions are summarized in Table 1 . A cleavage-resistant proNGF knock-in mouse exhibits cardiac microvascular endothelial activation, a decrease in pericyte process length, and increased vascular permeability, leading to lethal cardiomyopathy in adulthood (Siao et al. 2012) . Genetic approaches were conducted by Yang and collaborators and by Siao and collaborators to confirm that the observed phenotypes of the cleavage-resistant proBDNF and proNGF mouse lines were a gain of function of the precursors and not a consequence of the expected decrease in the mature forms (Siao et al. 2012; Yang et al. 2014) . Interestingly, recent reports have shown that proBDNF (Sun et al. 2012; Anastasia et al. 2013) as well as proNGF (Deinhardt et al. 2011) induce growth cone retraction in cultured neurons by interacting with p75NTR and the sortilin family member Vps10p-domain sorting receptor 2 (SorCS2).
Multiple active cleavage products from a proprotein precursor
Pre-pro-proteins can give rise to multiple active products generated after processing. Some interesting examples includes the insulin precursor preproinsulin and the proopiomelanocortin (POMC) precursor pre-POMC. Preproinsulin is a single polypeptide synthetized in pancreatic b-cells that holds a signal peptide (amino acid 1-24), followed by the insulin B chain (amino acids 25-54), a prodomain named C peptide (amino acids 57-87) and finally by insulin A chain (amino acids 90-110). After removal of the signal peptide, proinsulin undergoes cleavage by proconvertases and carboxypeptidase E to release the A and the B chains which are linked by two disulfide bonds to form mature insulin, and the C peptide (Steiner and Oyer 1967; Bell et al. 1980 ). The C peptide participates in the assembly and processing of insulin as a prodomain, but it has been shown to be a bioactive peptide on its own. Recent evidence suggests that the Gprotein coupled receptor 146 is the C peptide receptor (Yosten et al. 2013) . In particular, the C peptide promotes some anti-inflammatory, anti-oxidant and cell protective mechanisms (reviewed in Wahren and Larsson 2015) . Pre-POMC is a hormone precursor that undergoes several tissuespecific processing via cleavage by proconvertases to give rise to multiple active peptides ( The origin and selective pressures that give rise to all these important peptides in one gene and under the control of one set of promoters remains to be elucidated. The finding of multiple active cleavage products from a pro-protein precursor like POMC challenges the field to begin to explore other cleaved peptides from hormones and growth factors which were thought (with little or no evidence) to be degraded or non-functional after cleavage from a known functional domain.
A prodomain as an independent signaling ligand: pBDNF A previous study failed to detect the isolated BDNF prodomain (pBDNF) ); thus, it was thought to be rapidly degraded after processing of the proBDNF precursor. However, Dieni and collaborators found for the first time the isolated pBDNF in brain tissue (Dieni et al. 2012) . They suggested that pBDNF was not previously found because it was washed away from the western blot membranes after transference. They found that by fixing the transferred membranes with glutaraldehyde, they were able to reliably detect the pBDNF. In this context, it has been well-established that fixatives crosslink peptides to the transfer membrane and thus allow the retention and detection of some low molecular weight proteins (Karey and Sirbasku 1989; Kurien and Scofield 2009 ). Dieni and collaborators also showed that BDNF isoforms, including pBDNF are trafficked and stored in dense core vesicles like other growth factors and hormones (Dieni et al. 2012) . During late embryonic and early postnatal mice development, the expression of pBDNF in the hippocampus is negligible. However, the pBDNF is detected at postnatal day 5 (P5), and its expression increases significantly at 1 month plateauing in Table 1 . AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; BDNF, brain-derived neurotrophic factor; pBDNF, BDNF prodomain; proBDNF, pro-protein of the neurotrophin brain-derived neurotrophic factor; P75NTR, p75 neurotrophin receptor; SorCS2, Vps10p-domain sorting receptor 2.
Given the breadth of this field, it is difficult to include all contributions, and oversights are unintended. adult mice (3-9 months) (Anastasia et al. 2013) . This is in agreement with previous findings that mBDNF and pBDNF are the most abundant moieties during adulthood compared to proBDNF which is abundant during development (Yang et al. , 2014 Rauskolb et al. 2010; Dieni et al. 2012; Anastasia et al. 2013) . Subsequently, others have also detected pBDNF in brain tissues utilizing the same fixation technique and independent antibodies (Lee et al. 2015; Lim et al. 2015; Mizui et al. 2015; Guo et al. 2016; Yang et al. 2016) .
After Dieni and collaborators found the isolated pBDNF, we asked for the first time if this peptide could function as an independent signaling molecule (Anastasia et al. 2013) . First, we showed that pBDNF is secreted in an activitydependent manner from hippocampal neurons in culture (Anastasia et al. 2013) , similar to mBDNF (Goodman et al. 1996) and proBDNF Yang et al. 2009 ). Inhibition of extracellular cleavage of secreted proBDNF, using a-2 anti-plasmin and an inhibitor of numerous MMPs did not significantly change levels of secreted prodomain from neuronal culture, suggesting that most of the cleavage of proBDNF to pBDNF and mBDNF might occur in intracellular compartments (Anastasia et al. 2013) .
The high sequence conservation (pBDNF sequence is highly conserved in more than 70 species examined to date) and the fact that pBDNF can be secreted from neurons prompted to ask whether this protein can act as an active ligand. As discussed previously there is a human SNP in BDNF leading to a Val66Met substitution within the pBDNF sequence and highly correlated with the occurrence of neuropsychiatric disorders. Thus, it was attractive to evaluate if the Val and/or the Met-pBDNFs were active, and if they stimulated different biological functions. Up to date, three studies have addressed these questions. The first study (1) found that only the Met variant of pBDNF acutely alters neuronal morphology as this ligand induces growth cone retraction and collapse. In this study, the Val-pBDNF was inert as it did not affect growth cone shape (Anastasia et al. 2013) . The second study (2) showed that the Val-pBDNF facilitate hippocampal long-term depression, while the MetpBDNF variant prevented this effect (Mizui et al. 2015) . The third report (3) found that the Val-pBDNF reduces dendritic spine density in hippocampal neurons (Guo et al. 2016) . The key findings of these three publications are analyzed below and summarized in Table 1 .
(1) The proper development and establishment of functional neuronal networks rely, in part, on the emergence, path finding, and retractions of neuronal processes. Growth cones at the tip of growing neurites are actin-rich structures which can sense the environment to seek for their synaptic target. Disruption of the growth cone's normal pathfinding can lead to altered circuits that can ultimately affect human behavior, including pathological conditions such as neuropsychiatric disorders. Anastasia and collaborators found for the first time that the pBDNF is an active-independent signaling molecule: the Met variant of pBDNF (10 ng/mL) is capable of altering the normal development of growth cones in cultured neurons inducing freezing, retraction, and collapse of these structures (Fig. 1b and c) . This effect is mediated by Met-pBDNF engaging to a complex of two unrelated receptors: p75NTR and the SorCS2 (Anastasia et al. 2013) . Interestingly, both pBDNF variants appear to be intrinsically disordered proteins with some transient structural features as detected, using nuclear magnetic resonance and circular dichroism. However, both variants have specific conformational changes as a result of the substitution. In the residues neighboring the Val66Met substitution, the Val-pBDNF has an increased tendency to b-structure while the Met variant is more helical (represented in Fig. 1b and c) . These structural difference results in a differential interaction with the SorCS2 receptor which can explain their difference in activity. Other consequences of the Val66Met substitution on the biology of pBDNF have yet to be unveiled and may include differences in bio-availability, in intracellular trafficking, and/or in aggregation. If corroborated in vivo, Met-pBDNF-induced growth cone collapse during brain development could give rise to changes in circuitry that can explain why the Val66Met SNP carriers are more prone to developing neuropsychiatric disorders. Therefore, it would be an additional molecular explanation for the Val66Met phenotypes together with the loss function of mBDNF proposed earlier (Chen et al. 2006) . The Val-pBDNF was inert in growth cones even at higher concentrations (Anastasia et al. 2013) and the role of this variant in developing neurons requires further studies. A question that arises from this study is how p75NTR and SorCS2 receptors interact to transduce the MetpBDNF signal. It has been shown that p75NTR and SorCS2 cooperate to transduce proNGF signaling (Deinhardt et al. 2011) . In that case, proNGF prodomain binds to SorCS2 while the mature moiety of the precursor binds to p75NTR forming a trimeric signaling unit. The expression of p75NTR is necessary for triggering pBDNF signaling but this ligand only interacts with SorCS2 (Anastasia et al. 2013) . It has been shown that p75 neurotrophin receptor and SorCS2 complexes are present even in the absence of ligands (Deinhardt et al. 2011; Glerup et al. 2014) . Thus, we hypothesize that the Met-pBDNF/SorCS2 complex somehow activates p75NTR to induce growth cone retraction, but further experiments are required to test this possibility.
(2) Another function for pBDNF was shown by Mizui and collaborators, in that they demonstrated that the addition of ValpBDNF (10 ng/mL) facilitates LTD induction in hippocampal slices (Mizui et al. 2015) . This effect requires the activation of N-methyl-D-aspartate (NMDA) receptors containing the GluN2B subunit and the p75NTR receptor, but not the tropomyosin receptor kinase B. The endocytosis of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor is an important event in the expression of LTD and is triggered by NMDA receptor activation (Carroll et al. 2001) . The authors proposed that the Val-pBDNF increases GluN2B expression at the cell surface which then promotes the internalization of the AMPA receptor's GluA1 and GluA2 subunits, thus, resulting in LTD facilitation (Fig. 1d) . Moreover, they demonstrated that NMDA and the Val-pBDNF act additively to induce GluA2 internalization and LTD facilitation and that blocking the NMDA receptor prevented the ligand's effect. These results suggest that Val-pBDNF is upstream of the NMDA receptor on the signaling cascade inducing this neuroplasticity effect. Interestingly, the Met-pBDNF failed to induce LTD facilitation, and also prevented the NMDA-induced AMPA receptors internalization (Fig. 1e) . These differences between the variants open the question of how the Val version is active while the Met-pBDNF is inert, and which is/are the coreceptor/s involved, other than p75NTR.
(3) Guo and collaborators tested the Val-pBDNF in mature primary hippocampal neurons and showed that this ligand induces a reduction in dendritic spines density (Fig. 1f) (Guo et al. 2016) . Notably, this effect was evident 24 h after the administration of the ligand, but not earlier. They did not test the effects of the Met-pBDNF on dendritic spines. Later on, the authors performed yeast two-hybrid, cross-linking and pull downs followed by mass spectrometry, and protein-protein interaction chips to shed light on the mechanism underlying this morphological effect. Surprisingly, they could not detect pBDNF interactions with SorCS2 which is the only reported receptor for the isolated prodomain demonstrated by coimmunoprecipitation and nuclear magnetic resonance (Anastasia et al. 2013 ). The p75NTR receptor, which is somehow required to trigger the pBDNF effects (Anastasia et al. 2013; Mizui et al. 2015) , does not interact directly with pBDNF (Anastasia et al. 2013) . Using those unbiased methods, Guo and collaborators supported this observation. Unfortunately, the interaction screening data are not available in their report. They propose that the mechanism for the Val-pBDNF effect on dendritic spines includes a mitochondrial pathway. In particular, they showed that the Val-pBDNF induces mitochondrial elongation, release of cytochrome c to the cytosol, and finally caspase 3 activation which alters dendritic spine number. It is important to mention that Guo and collaborators utilized 50 ng/mL of recombinant Val-pBDNF for their studies. Anastasia and collaborators showed that 50 ng/mL of the Val-pBDNF remains inactive without showing significant growth cone retraction (Anastasia et al. 2013) .
One of the major challenges in the study of prodomain biology is the difficulty of generating antibodies that exclusively recognize the pro-sequence, but not the precursor pro-protein which obviously includes the prodomain. Previous studies have used a monoclonal antibody (mAb287, available at GeneCopoeia, Rockville, MD, USA) Anastasia et al. 2013; Mizui et al. 2015) , or a polyclonal (ANT-006 from Alomone Labs, Jerusalem, Israel) (Dieni et al. 2012 ) to detect pBDNF, although both antibodies were raised against proBDNF. It's important to mention that different batches of the Alomone proBDNF antibody have shown variability in detecting pBDNF as it has successfully detected pBDNF in a study (Dieni et al. 2012) , but it detected an unspecific 18-19 kDa band in another work (Anastasia et al. 2013 ). Guo and collaborators generated an antibody specifically against pBDNF which recognizes an epitope in generated after furin processing of proBDNF (Guo et al. 2016) . The authors claim that this antibody does not recognize proBDNF. Using this antibody they confirmed previously reported data showing the detection of pBDNF in hippocampal neurons and the release of pBDNF in an activity dependent manner.
In addition to these three initial publications, the biological actions of pBDNF have been recently studied by others. Increased pBDNF levels have been correlated with stress resilience (Yang et al. 2016) , and with nicotine withdrawalinduced anxiety (Lee et al. 2015) . Interestingly, there is a synergistic interaction between the amyloid-b and MetpBDNF in the induction of toxicity of SH-SY5Y human neuroblastoma cell lines (Lim et al. 2015) . However, these experiments were performed with very high Met-pBDNF concentrations (200 ng/mL), most likely out of the physiological range. Lim and collaborators also showed that pBDNF levels are significantly increased in a subset of postmortem hippocampal lysates from advanced Alzheimer's disease patients (Lim et al. 2015) . These interesting results suggest, for the first time, that pBDNF could be a therapeutic target involved in the pathogenesis of the disease.
In addition to pBDNF, the only other neurotrophin prodomain that has been evaluated for biological activity is the NGF prodomain. The NGF prodomain has been shown to induce death of PC12 cells (Armugam et al. 2012) . However, the NGF prodomain was inert on the induction of LTD (Mizui et al. 2015) and did not affect dendritic spines density in primary neuronal cultures (Guo et al. 2016) . The significance of these findings is relative as the endogenous NGF prodomain has not been found yet in neural tissues or primary neurons. Apart from the neurotrophin family, another growth factor prodomain has been tested for activity: fragments of the glial cell line-derived neurotrophic factor (GDNF) prodomain, carrying the term dopamine neuron stimulating peptides (DNSP), has also been shown to be active as they display robust neurotrophic actions similar to mature GDNF (Bradley et al. 2010; Stenslik et al. 2015) . DNPSs and mature GDNF promote similar actions in neurons, in contrast to pBDNF and mBDNF which display opposing effects.
Conclusions and perspectives
All these reports together support the idea that several growth factors and hormones prodomains have novel and overlooked physiological and/or pathological functions. In general, prodomains were thought to be transient species, which were quickly degraded after cleavage of their respective precursor pro-proteins. However, recent reports have demonstrated that prodomains and mature domains co-exist and both peptides can be secreted to the extracellular space. Interestingly, some of these prodomains are part of active precursors while some have independent (even antagonistic) functions. The BDNF pro-peptide (pBDNF) was undetected for some time despite efforts developed by several groups (Yang et al. 2009 and unpublished experiments) . The combination of specific antibodies and crosslinking of the proteins to the transfer membrane after western blotting allowed the detection of significant amounts of pBDNF in neuronal tissues and primary neurons. In the future, other isolated growth factors and hormones prodomains may be discovered in the nervous system, using this biochemical technique together with new specific antibodies.
BDNF is one of the most widely expressed trophic factors in the nervous system (Conner et al. 1997) . Its functions ranges from survival and differentiation of neural stem cell, neuron survival, axon-dendrite differentiation, synapse formation, and maintenance, to development and regulation of neural circuits (Park and Poo 2013) . BDNF is also expressed and active in non-neuronal cells such as endothelial cells, smooth muscle cells, immune cells, and epithelial cells in different organs (Kermani and Hempstead 2007; Anastasia et al. 2014) . As pBDNF and mBDNF are stored and secreted from the same dense core vesicles (Dieni et al. 2012) , we speculate that pBDNF is a potential active ligand in every cell and tissue where mBDNF has been shown to be released. Thus, it is very important to study the presence of this isolated prodomain and new potential local actions in these scenarios. Moreover, functions previously attributed to proBDNF should be reconsidered and/or reinterpreted in light of the existence of pBDNF, which is more abundant than the precursor during adulthood.
The main question that arises from active prodomains is why two or more proteins with different or even opposing effects are synthetized from the same gene or exon. A possible answer is that the biological functions regulated by these gene products are extremely important for the homeostasis of the nervous system. Thus, different peptides with different functions can precisely regulate the fine-tuning of the system. We propose that for some hormones and growth factors the nomenclature 'prodomain' and 'mature domain' should be revisited because fragments that were considered merely to aid the synthetizes of an active domains are bioactive by themselves.
